Plants and mental disorders: the case of Catalan linguistic area

Laia N. Irún1, Airy Gras1,2*,†, Montse Parada2 and Teresa Garnatje1

1Institut Botànic de Barcelona (IBB), CSIC-Ajuntament de Barcelona, Barcelona, Spain, 2Laboratori de Botànica—Unitat Associada CSIC, Facultat de Farmàcia—Institut de Recerca de la Biodiversitat—IRBio, Universitat de Barcelona, Barcelona, Spain

Introduction: Mental disorders are among the leading causes of ill-health and disability worldwide. Despite the disease burden they cause, including significant direct and indirect impacts on individual’s health and major social and economic consequences in all countries of the world, it is still one of the most neglected areas of public health. In such a context, the medicinal plants traditionally used to pall these pathologies are presented as a promising tool for future drug development for the management of mental health disorders. The aim of the present study is to analyze the information about plant species used to treat mental disorders in the Catalan linguistic area (CLA) and compare these traditional uses with pharmacological literature in order to evaluate the most quoted taxa and their uses and to provide a basis for further research.

Methods: Data have been recovered from the “Etnobotànica dels Països Catalans” webpage (https://etnobotanica.iec.cat/) and the meta-analytic work carried out in the present study covers 27 prospections performed in different territories between 1990 and 2019. Descriptive statistics and quantitative ethnobotany were carried out and some ethnobotanical indices were calculated.

Results and Discussion: The number of use reports analysed to treat mental disorders in CLA is 2,544 spread over 183 taxa belonging to 64 families, being the most cited the Malvaceae (29.36% of use reports), Lamiaceae (16.71%), Caprifoliaceae (7.94%), Rutaceae (7.47%) and Papaveraceae (6.01%). The most used taxa to treat or alleviate the mental disorders have been Tilia platyphyllos Scop. (24.53%), Valeriana officinalis L. (7.47%), Salvia officinalis L. (5.07%), Sambucus nigra L. (4.28%), and Ruta chalepensis L. (3.89%). The flowers or inflorescences (47.68%), followed by aerial part (23.49%), have been the most used plant parts, and tisane the most commonly used pharmaceutical form (78.03%). The most reported use is as sedative with 40.92%, followed by anticephalalgic (21.19%) and tranquilizer (20.01%). The informant consensus factor (FIC) was 0.93, and 3.72% was the ethnobotanicity index (EI) value. The information is coincidental with at least one of the comprehensive pharmacological literature sources checked for 73.68% of ethnobotanical uses.

KEYWORDS
Catalan linguistic area, ethnobotany, Iberian Peninsula, medicinal plants, mental disorders, mental health, traditional knowledge

Abbreviations: CI, Cultural Importance Index; CLA, Catalan linguistic area; EI, Ethnobotanicity Index; EMA, European Medicine Agency; ESCOP, European Scientific Cooperative on Phytotherapy; Fc, Informant Consensus Factor; MI index, Medicinal Importance index; UR, Use Reports; WHO, World Health Organization.
1 Introduction

Mental health and physical health are equally important components of a holistic concept of health. The first one, sometimes underestimated, includes our emotional, psychological, and social well-being and it affects how we think, feel, and act in every stage of life, from childhood through adulthood (CDC, 2021). Mental disorders refer collectively to all diagnosable mental health problems, including a large range of symptoms and conditions affecting the mood, thinking and behavior, causing distress and impairment in the family, work and social areas of the individual. Although most troubles are clearly typified, the cultural context of the individual must be considered (Njoku, 2022).

According to World Health Organization (WHO) global health estimates, in 2021 more than 150 million people in the WHO European Region lived with a mental health condition (including depression, anxiety disorders and psychosis in adults, as well as developmental and behavioral disorders in children and adolescents), equivalent to 20% of the European population (WHO, 2022a).

Furthermore, mental health is interconnected with physical and social functioning, as well as health status, with a proven 10–25 years’ reduction in life expectancy for patients with severe mental disorders. Additionally, they are also attributed to a significant number of indirect deaths, since people with those pathologies have higher rates of suffering other troubles, such as type II diabetes or respiratory and cardiovascular diseases, and are more likely to commit suicide (WHO, 2013).

In addition, psychologists and mental health professionals speculate that the COVID-19 pandemic has had a further impact on the mental health of the global population, with the increase in cases of depression, suicide, and self-harm, apart from other symptoms reported globally due to the pandemic (Li et al., 2020; Moukaddam and Shah, 2020; Kumar and Nayar, 2021).

Despite these figures, mental health is one of the most neglected areas of public health, as the global median of government health expenditure that goes to mental health is less than 2% (UNICEF, 2021; WHO, 2022b), whereas the economic, social and individual burden of mental illness have clear implications in the development of the countries, with indirect costs in the labormarket, driven by lower employment rates and reduced productivity (WHO, 2018). Moreover, poor mental health was estimated to cost the world economy approximately 2.5 trillion dollars per year, a cost projected to rise to 6 trillion dollars by 2030 (The Lancet Global Health, 2020).

Despite the significant burden mental disorders impose on society, the investment and pharmaceutical innovation in this disease area remains comparatively low (MacEwan et al., 2016). In consequence, there is a need for the development of evidence-based tools and innovations for better treatments and services (WHO, 2021). In the 21st century, the pharmacological effects of medicinal plants have been considered promising for the management of healthcare (Cragg and Newman, 2013). Thereby, the key role of ethnopharmacology is to provide new approaches and novel solutions, giving to pharmaceutical companies’ supplementary knowledge about plants that can lead to innovative drugs (Heinrich and Jäger, 2015). Moreover, the benefits of plants in mental pathologies have already been reported (Parilli-Moser et al., 2021; Sarris et al., 2021; Sala-Vila et al., 2022). However, the ethnobotanical approach remains to be explored, since very few detailed monographies based on ethnobotanical studies on medicinal plants used in the treatment of mental illnesses are recorded in the literature, most of them based on African population (Romeiras et al., 2012; Ior et al., 2017; Shirungu and Cheikhroussel, 2018; Wubetu et al., 2018; Mabaleha et al., 2019). In Europe, the ethnobotanical publications focused on mental health data are not so common (Calvo and Caver, 2015; Motti and de Falco, 2021), but this does not mean those kinds of data are not collected during the fieldwork.

The Catalan linguistic area (CLA) is one of the most largely studied territories in Europe from the ethnobotanical point of view (Vallès, 2019), and some of the general studies show data of plants used against mental conditions (Gras et al., 2019; Gras et al., 2020), but this subject has never been addressed as a focus of the study.

Therefore, the aims of the present study are i) to analyse information about plant species used to treat mental disorders in CLA: ii) to compare these traditional uses with pharmacological literature in order to evaluate the most quoted taxa and their uses and to provide a basis for further research.

2 Material and methods

2.1 Study area

The area covered by the present study includes some territories of the CLA, which are the group of territories where Catalan is the traditional language. The Catalan linguistic area has an extension of ca. 70,000 km² (Bolòs et al., 2005) and around 14,000,000 inhabitants (Departament, 2021; IBESTAT, 2021; IDESCAT, 2021; ISTAT, 2021; Portal Estadístic de la Generalitat Valenciana, 2022) belonging to four states: Andorra, France (Northern Catalonia or eastern Pyrenees department), Italy (L’Alguer, Sardinia), and Spain (Balearic Islands, Canur–a small area in Murcia, Catalonia, a portion of eastern Aragon, and Valencia).

The wide diversity of landscape from the Mediterranean Sea level to 3,143 m a.s.l. in Pica d’Estats (Pyrenees) gives rise to a wide floristic diversity (Bolòs et al., 2005), harbouring approximately 4,300 autochthonous and 1,200 allochthonous plant taxa, including species and subspecies (Sáez, pers. comm.).

2.2 Databasing and data selection

The information analysed on the present paper has been collected through semi-structured ethnobotanical interviews (Pujadas et al., 2004) following the ethical principles of the International Society of Ethnobiology (ISE, 2023) and is included in the ‘Etnobotànica dels Països Catalans’ webpage (https://etnobotanica.iec.cat/) (Garnatje et al., 2021). Herbarium vouchers collected during the interviews are deposited in the herbarium BGN (Centre de Documentació de Biodiversitat Vegetal, Universitat de Barcelona). Bolòs et al.’s (2005) have been followed for taxa nomenclature, which is a flora covering specifically the area considered. In addition, Plants of the World Online (https://powo.science.kew.org) has been used for
the allochtonous plants. The family attribution is performed following APG IV, the last Angiosperm Phylogeny Group’s arrangement to date (APG, 2016).

The information concerning mental disorders has been recovered from the mentioned database and the meta-analytic work carried out in the present study covers 27 prospections performed in different territories between 1990 and 2019 (Figure 1).

2.3 Data analyses

Descriptive statistics and quantitative ethnobotany were carried out using Excel (Microsoft Excel 2016), and the use report (Vandebroek et al., 2008) has been used as a unit of analysis. The relationship between the most quoted plants and their uses was visualized by an alluvial diagram using RAWGraphs (Mauri et al., 2017).

In addition, some ethnobotanical indices were calculated: 1) the informant consensus factor ($F_{IC}$; Trotter and Logan, 1986), the ratio of the number of use reports minus the number of plant taxa used to the number of use reports minus one, in order to assess the consistency or robustness of the traditional knowledge regarding mental disorders; 2) the ethnobotanicity index (EI; Portères, 1970), the quotient between the number of plant taxa used (here taking into account the plants used for mental disorders), and the total number of plant taxa that constitute the flora of the territory (autochthonous plants, see previous estimation), expressed as a percentage, in order to have a general idea of the relevance of these plants in the area considered and to compare with the same index in studies focused on other human body systems; 3) the cultural importance index (CI; Tardío and Pardo-de-Santayana, 2008), the sum of the proportion of informants that mention each taxon use, has also been calculated to identify the most valued plants by the informants; and 4) the medicinal importance index (MI; Carrió and Vallès, 2012), the quotient between the total use reports for a specific use category and the number of plant taxa possessing this use, to evaluate the real importance of the use.

A minor bias in relation to number of use reports and related analyses exists, as in one of the studies included in the dataset (Mulet, 1990), each taxon is assigned to a municipality, instead of an informant, which is the case in all the other works.
2.4 Pharmacological comparison in the literature

Apart from reviewing the taxa quoted to treat mental disorders in CLA, a comparison, whenever possible, was done. The activity of the plants reported was checked in pharmacological sources as official monographs (EMA European Medicines Agency, 2022; ESCOP, 2022) and encyclopedic bibliography on phytotherapy (Blumenthal, 2003; Duke, 2003; net, 2022). The aim of this comparison, done for the twenty-five most quoted taxa, is to contrast the medicinal uses reported by the informants with pharmacological literature, thus looking for plants with potential applications, not recorded in literature, which could be of interest to develop further studies and to design new drugs.

Moreover, to correlate the medicinal uses reported with the mental disorders they are associated to, a literature search has been performed, using the two well-established systems for the classification of mental disorders: The Diagnostic and Statistical Manual of Mental Disorders IV and V, edited by the American Psychiatric Association (APA, 1994; APA, 2013); and the International Classification of Diseases by the World Health Organization (ICD, 2022).

3 Results and discussion

3.1 General data

The number of use reports collected and analysed to treat or alleviate mental disorders and associated symptoms in CLA was 2,544, and this information came from 1,082 informants. This complete dataset is available in the appendix (Appendix A). In total, 183 taxa—eight of them determined only at genus level and 14 at infraspecific level—are quoted to treat seventeen illnesses classified as mental disorders. Taxa are distributed among 64 families and the most cited ones, representing around 70% of total use reports, were Malvaceae (29.36%, 6 taxa), Lamiaceae (16.71%, 30 taxa), Caprifoliaceae (7.94%, 6 taxa), Rutaceae (7.47%, 5 taxa) and Papaveraceae (6.01%, 4 taxa).

Unlike general ethnobotanical studies in CLA (Gras et al., 2020; Gras et al., 2021a), the most cited families are not the ones recurrently found, except for Lamiaceae, which is the second most quoted family and the most diverse in quoted taxa, followed by Asteraceae (4.91%, 18 taxa) and Rosaceae (3.66%, 10 taxa), all of them common and abundant in the Mediterranean flora (Gardner and Gardner, 2019). Moreover, the number of use reports of some of the most cited families (Malvaceae, Caprifoliaceae, Rutaceae and Papaveraceae) refers to a few taxa, meaning that there exists a large consensus on the use of these species for the treatment of mental disorders. It is worth mentioning that Malvaceae, not frequent among the top families in ethnobotanical studies, has incorporated the families Sterculiaceae and Tiliaceae and that Malvaceae, not frequent among the top families in species for the treatment of mental disorders. It is worth mentioning that in CLA (Gras et al., 2020; Jarić et al., 2014; Calvo and Cavero, 2015; Motti and de Falco, 2021) and in this study it represents 28.62% of the reports, fact that justifies the Malvaceae as the first quoted family. The roots of V. officinalis are also well known and established in this field (Borràs et al., 2021), and a big set of its products can be found in the market as sedative and to treat insomnia. Less frequent in the market but very quoted in this study are S. officinalis, S. nigra and R. chalepensis, mostly used as anticephalalgic. Cephalalgia and migraine are considered neurological disorders with a broad range of psychiatric comorbidities (APA, 2013; ICD, 2022). The most common pharmaceutical forms for these taxa and specific use are aerosol, fumigation and essences, normally not quoted as the most popular in ethnobotanical studies. The last taxon mentioned, R. chalepensis, is also very common among informants, mainly used as sedative and tranquilizer, taken as herbal tea or infused in chocolate, but caution should be exercised given its use as abortifacient (Gras et al., 2020; Gras et al., 2021b).

The cultural importance (CI) index was calculated for all the taxa (Supplementary Table S1). This parameter indicates the degree of agreement in plant use among informants, as it considers not only the spread of the use (number of informants for each species), reported in Supplementary Table S1, but also its versatility, i.e., the diversity of its uses, reported in Table 1. In the present study, the highest CI values are represented by T. platyphylllos (0.58), V. officinalis (0.18), S. officinalis (0.12), S. nigra (0.10) and R. chalepensis (0.09), and coincide with the most cited plants.

The five taxa mentioned before represent around 45% of the use reports, and the twenty-five most quoted taxa are almost 80%. Among these twenty-five taxa we can find well-known plants used in phytotherapy to treat mental disorders as Hypericum.
TABLE 1 Medicinal uses to treat mental disorders and values of total use reports (UR), total use reports percentage and medicinal importance index.

<table>
<thead>
<tr>
<th>Medicinal use</th>
<th>Total UR</th>
<th>Total UR (%)</th>
<th>Total taxa</th>
<th>MI index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedative</td>
<td>1041</td>
<td>40.92</td>
<td>66</td>
<td>15.74</td>
</tr>
<tr>
<td>Anticephalalgic</td>
<td>539</td>
<td>21.19</td>
<td>74</td>
<td>7.26</td>
</tr>
<tr>
<td>Tranquilizer</td>
<td>509</td>
<td>20.01</td>
<td>61</td>
<td>7.77</td>
</tr>
<tr>
<td>Hypnotic</td>
<td>154</td>
<td>6.05</td>
<td>28</td>
<td>5.50</td>
</tr>
<tr>
<td>Antidysthmic</td>
<td>90</td>
<td>3.54</td>
<td>13</td>
<td>6.69</td>
</tr>
<tr>
<td>Antidepressant</td>
<td>82</td>
<td>3.22</td>
<td>22</td>
<td>3.73</td>
</tr>
<tr>
<td>For boost brain</td>
<td>35</td>
<td>1.38</td>
<td>14</td>
<td>2.50</td>
</tr>
<tr>
<td>Aphrodisiac</td>
<td>31</td>
<td>1.22</td>
<td>17</td>
<td>1.76</td>
</tr>
<tr>
<td>Antimigraine</td>
<td>21</td>
<td>0.83</td>
<td>13</td>
<td>1.62</td>
</tr>
<tr>
<td>For tobacco disaccustom</td>
<td>11</td>
<td>0.43</td>
<td>5</td>
<td>2.20</td>
</tr>
<tr>
<td>Anaphrodisiac</td>
<td>8</td>
<td>0.31</td>
<td>6</td>
<td>1.33</td>
</tr>
<tr>
<td>For alcohol disaccustom</td>
<td>6</td>
<td>0.24</td>
<td>4</td>
<td>1.50</td>
</tr>
<tr>
<td>For the fright</td>
<td>5</td>
<td>0.20</td>
<td>3</td>
<td>1.67</td>
</tr>
<tr>
<td>For onychophagy</td>
<td>4</td>
<td>0.16</td>
<td>1</td>
<td>4.00</td>
</tr>
<tr>
<td>For chorea</td>
<td>3</td>
<td>0.12</td>
<td>3</td>
<td>1.00</td>
</tr>
<tr>
<td>Antiepileptic</td>
<td>3</td>
<td>0.12</td>
<td>3</td>
<td>1.00</td>
</tr>
<tr>
<td>Antiparkinsonian</td>
<td>2</td>
<td>0.08</td>
<td>2</td>
<td>1.00</td>
</tr>
</tbody>
</table>

FIGURE 2
The twenty-five most cited plants and their medicinal uses quoted in the studied area.
The medicinal importance index was calculated for all the medicinal use categories, and the results range from 1.00 to 15.74 (Table 1). The highest medicinal importance indices correspond to the most quoted uses, sedative (15.74), followed by the tranquilizer (7.77) and anticephalalgic (7.26).

The main mental conditions treated in CLA using the two well-established systems for the classifications of mental disorders (APA, 2013; ICD, 2022) are neurocognitive, anxiety, sleep, sexual behavior and depressive disorders. Therefore, plants traditionally used against the mental conditions in CLA, would have applications mainly in these kind of pathologies.

Concerning the pharmaceutical forms used, the form is indicated in 95.56% of the reports, while the remaining 4.44% has not been recorded. Among the reported forms, 89.80% are for internal use and 10.20% for external use. In total, 28 pharmaceutical forms are employed and tisane, including decoction and infusion, represents 78.03% of the total reports, followed by far by direct use (internal or external) with 6.71%. Tisane is a very common pharmaceutical form in popular medicine and the data presented in this study confirms that fact one more time (Calvo and Cavero, 2015; Gras et al., 2021b). Among the five most reported pharmaceutical forms are also fumigation (3.29%) and aerosol (2.92%).

3.4 Pharmacological comparison

The 25 most quoted taxa and their medicinal uses against mental disorders in CLA have been compared at the pharmacological level by reviewing official monographs and encyclopedic bibliographies on phytotherapy. Among the 114 checked uses, the information was consistent with at least one of the pharmacological sources for 73.68% ethnobotanical uses (Supplementary Table S1). By far, Duke’s CRC Handbook of Medicinal Herbs (2003) with 23 taxa and 71.05% of coinciding uses is the most inclusive and detailed work analysed, followed by net (2022) (13 taxa, 17.54%), EMA (2023) (8 taxa, 11.40%), Blumenthal (2003) (4 taxa, 5.26%) and ESCOP (2022) (3 taxa, 3.51%).

The plants quoted on ethnobotanical studies are the basis to develop traditional herbal medicinal products. The European Parliament Directive (2004/24/EC) approves that the long tradition of medicinal products simplified registration procedures and reduces the need for clinical trials, to the extend the efficacy of the medicinal product is plausible based on long-standing use and experience (European Parliament, 2004). A clear example of this could be the well-known popular use of S. nigra or S. officinalis as anticephalalgic in the CLA. Focusing on the results of our study, further pharmacological investigations should be done. Furthermore, additional studies of J. saxatilis and S. chamaecyparissus uses, quoted in another Iberian Peninsula territory (Calvo and Cavero, 2015), could be interesting to explore.

4 Concluding remarks

The present study is the first one in the Iberian Peninsula, specifically in CLA focused on plants used to address mental disorders, and still one of the very few in Europe on this subject.

This work allows to give a perspective of the current ethnobotanical data applied to mental disorders collected so far, reflecting the data.
recorded since 1990 on plants traditionally used in CLA for this type of disorders. In total, a compendium of 183 taxa is quoted to treat seventeen illnesses and associated symptoms classified as mental disorders. The dataset analysed and the results presented here, demonstrate the established tradition in CLA of using plants as additional or alternative treatment to alleviate or cure the mental disorders. At the same time, the present study has assessed which of these uses are supported by pharmacological literature, showing a considerable agreement between folk and pharmacological sources, and giving a list of species that, having a great representation in the folk medicine, are not reported in official monographs. These data may be the starting point for further research with the aim to obtain alternative products to conventional treatment. Phytochemical and pharmacological studies on some of the plants quoted here would be a useful first step in this process.

The importance of ethnobotany should also be emphasized because, as shown here, this science has a great potential to become a key step in drug development. Moreover, in a world in which the optimization of all systems is sought, it is important to look at the past from the present in order to face the future with new interpretations. In this line, ethnobotany is necessary to use these and rely on them for the development of new drugs and applications.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

LI: Conceptualization, Formal Analysis, Methodolog, Writing–original draft. AG: Conceptualization, Data curation, Formal Analysis, Methodolog, Writing–original draft. MP: Data curation, Writing–review and editing. TG: Conceptualization, Formal Analysis, Methodolog, Writing–original draft.

Funding

This research was funded by projects 2017SGR001116 and CLT051/21/000005 from the Generalitat de Catalunya (Catalan Government), and PRO 2020/2021/2022/2023-S02-VALLES from the Institut d’Estudis Catalans (IEC, Catalan Academy of Sciences and Humanities). AG benefited from a postdoctoral contract of project CGL2017-84297-R of the Spanish government and a postdoctoral grant of the Universitat de Barcelona funded by Next-Generation EU funds (Margarita Salas 2022–2024).

Acknowledgments

We are thankful to all the informants who offered us, through the years, their traditional knowledge on plants and to all colleagues who participated in any ethnobotanical survey in the area studied. Prof. Joan Valles for his involvement and leadership in many of the fieldwork carried out included in this work. Dr. Eva Castells and Dr. Miquel Ninyerola for their insightful comments, suggestions and ideas.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1256225/full#supplementary-material

SUPPLEMENTARY TABLE S1
The twenty-five most cited plants to alleviate or treat mental disorders in the studied area, with the medicinal uses, the number of total use reports (UR) and percentage and the Cultural Importance (CI) index. Comparison of uses in pharmacological comprehensive literature: (1) EMA (2022), (2) ESCOP (2022), (3) Fitoterapia.net (2021), (4) Duke (2003), (5) Blumenthal (2003)

References


Portal Estadístic de la Generalitat Valenciana (2022). Available at: https://pev.gva.es/va/


